Abstract | The techniques and materials used during percutaneous coronary intervention have advanced considerably over the past 3 decades, yet restenosis remains one of the major drawbacks of this procedure. Many innovative technologies, including drug-eluting stents, with or without specific polymers, and fully biodegradable stents have been and continue to be developed in the search for a safe and effective antirestenosis therapy. Remarkable advances in stent design and nanoparticle delivery systems ('nanovehicles') have already fueled revolutionary changes in the prevention and treatment of in-stent restenosis. In this Review we provide an overview of the latest innovations for optimizing outcomes of coronary stenting, and up-to-date information about prevention and treatment of in-stent restenosis.
Introduction
Since its introduction in the late 1970s, 1 percutaneous coronary intervention (PCI) has become the most important and widely used treatment for patients with obstructive coronary disease. Although the technique and the materials used during the procedure have advanced tremendously, restenosis-the renarrowing of the treated obstruction-remains one of the major complications of PCI.
2 Intravascular stents were developed as an adjunct to primary angioplasty for the management of early complications, including arterial dissection, and for the treatment for early elastic recoil. Despite the beneficial effects of stenting, however, rates of restenosis remained persistently high, giving rise to a new problem-in-stent restenosis (ISR). The introduction of drug-eluting stents (DESs) was seen as a solution to this problem and, initially, DESs reduced the incidence of ISR considerably. 3 However, these promising results led to increased use of DESs in a diverse range of complex coronary lesions, and for off-label indications, leading to a resurge in the rates of ISR. 4, 5 In light of the increasing number of PCI procedures being performed, the difficulty of treating ISR, and the increasing cost of adjuvant medication and devices, defining subsets of patients at increased risk for restenosis would be useful. These patients could benefit from additional treatment modalities. Until now, identifica tion of subgroups has been only partially successful, as was discussed in detail in Part 1 of this Review. 6 The ongoing efforts to better understand the underlying pathophysio logical mechanisms of resteno sis and vascular biology continuously fuel research on the prevention and treatment of ISR. Here, in Part 2 of the Review, we will assess the most important innovations for optimizing the outcomes of coronary stenting, and data on the prevention and treatment of restenosis in general, and ISR in parti cular, published in the 5-year period up to August 2011.
Prevention of restenosis
In general, PCI with DESs is currently the best approach for the prevention of restenosis. 7 However, safety concerns about stent malapposition, late stent thrombosis, and delayed restenosis have arisen. 8, 9 The main cause of these problems has, in addition to patient-related and lesion-related factors, been attributed to the stent polymer. 10 Additionally, the eluted antiproliferative agent and the stent platform (metal alloys and strut thickness) have been implicated in ISR. These concerns have fueled research in stent development, utilizing new antiproliferative agents, polymer technology, and metal stent platforms (Table 1) .
Antiproliferative agents
Sirolimus (rapamycin)-eluting stents (SESs; Cypher ® , Cordis Corporation, Bridgewater, NJ, USA) and paclitaxeleluting stents (PESs; Taxus ® , Boston Scientific, Maple Grove, MN, USA) were the first two DESs to be approved by the FDA for use in humans (in 2003 and 2004 , respectively). Although they both effectively reduce rates of resteno sis compared with bare-metal stents (BMSs), their local adverse effects on the vasculature are fairly divergent. High concentrations of locally released paclitaxel have been shown to have detrimental effects on the vascular wall in a mouse model, 11 suggesting a narrower thera peutic range of this potent drug. On the other hand, sirolimus has a less-harmful effect than paclitaxel on the vascular wall. 11 Data from comparisons of first-generation DESs show that PESs are associated with a higher risk of ISR and stent thrombosis than SESs. 7, 12 Two stents eluting sirolimus analogs-everolimus (Xience V ® , Abbott Cardiovascular Systems, Inc., Santa Clara, CA, USA) and zotarolimus (Endeavor ® , Medtronic Vascular, Inc., Santa Rosa, CA, USA)-have also been approved by the FDA. Many studies have been dedicated to comparing the various available DESs. In 2011, the 2-year follow-up results of two large-scale, randomized, controlled trials showed a sustained benefit of everolimus-eluting stents (EESs) over PESs in terms of safety and efficacy. 13, 14 On the other hand, zotarolimus-eluting stents (ZESs) were found to have a higher angiographic restenosis rate compared with PESs, although clinically driven repeat re vascularization rates were similar for both stent types. 15 In patients receiving routine clinical care, SESs have proven to be superior to ZESs. 16 The 2-year outcomes of the RESOLUTE All Comers trial 17 showed sustained similar safety and efficacy between ZESs and EESs. Unfortunately, few data are available on the direct EES versus SES comparison. Therefore, sirolimus and its analogs seem to be marginally superior to paclitaxel, whereas differences between the various limus-eluting stents remain to be elucidated.
In search for greater antirestenotic efficacy and improved long-term safety, new compounds specifically designed for use with DESs are being developed and studied. Biolimus A9 is a novel rapamycin derivative that, like sirolimus, inhibits smooth muscle cell proliferation via binding to the FK506-binding protein 1A and subsequent inhibition of the mammalian target of rapamycin (mTOR) and is specifically developed for local delivery to coronary arteries ( Figure 1) . 18 Besides its anti-inflammatory and antiproliferative potential and improved pharmacokinetic profile, the increased lipophilicity of biolimus A9 improves uptake by the coronary vessel wall, resulting in a more localized effect and lower systemic drug exposure 19 than sirolimus eluted from the Cypher ® stent. 20, 21 Compared with first-generation DESs, biolimus A9-eluting stents (BESs) have been shown to be associated with better recovery of endothelial function in coronary arteries, which could be partly explained by the better drug release kinetics. 22 Key points ■ Although drug-eluting stents decrease the incidence of restenosis, they do not yet fully prevent this problem; furthermore, long-term safety issues indicate that new technologies are still warranted ■ New-generation polymer coatings, including biocompatible permanent polymers and biodegradable polymers, and stents without a polymer, represent innovative technologies that aim to preserve vascular biology in the long term ■ Biodegradable stents prevent the long-term problems associated with foreign material in the coronary arteries; the first human studies employing these stents show promising results ■ Nanoparticle-mediated drug delivery systems are expected to revolutionize the development of innovative therapeutic devices, allowing local or targeted delivery of the drug with an excellent biocompatibility profile ■ Drug-eluting balloons provide homogenous drug distribution in the vascular wall and represent a favorable option for the treatment of restenosis ■ Gene-eluting stents are expected to play an important role in the prevention of in-stent restenosis, particularly in patients with a high genetic-risk profile
Novolimus is a metabolite of sirolimus and represents another new antiproliferative mTOR inhibitor specifically developed for the stent. The newly developed DESyne ® (Elixir Medical, Sunnyvale, CA, USA) novolimus-eluting stent has been tested in a clinical study, showing superi ority over ZESs regarding angiographic in-stent late loss. 23 Polymer technology New-generation polymer coatings have been produced with the specific aim of mimicking the endothelial lining in order to prevent late thrombotic complications. Basic research has shown that some polymeric materials could potentially upregulate genes related to inflammation, prolifer ation, thrombosis, and vasoconstriction 24 -processes that are considered to be pivotal in the develop ment of restenosis. 6 One example of current progress is the Biolinx ® (Medtronic Vascular, Inc.) polymer, currently used in the Endeavor Resolute ® ZES. This blend of three different polymers-the hydrophobic C10 polymer to control drug release, the biocompatible and hydrophilic C19 polymer, and polyvinyl pyrrolidone-allows an early burst followed by controlled drug release 25 so that at least 85% of the zotarolimus is released within 60 days and the remainder within 180 days, avoiding long-term release of the drug. Such release patterns are designed to match the delayed healing times seen in complex lesions. The Resolute ® ZES was shown to significantly lower target lesion revasculariza tion (TLR) compared with an earlier Endeavor ® ZES, which utilized a phosphorylcholine coating. 26 Another polymer, polyzene-F is highly biocompatible and has anti-inflammatory, bacteria-resistant, and prohealing qualities. The coating ensures that the stent has a very low surface thrombogenicity, potentially reducing the risk of stent thrombosis. Evaluation of cobalt chromi um stents nanocoated with polyzene-F in an animal model yielded favorable results. 27 Preliminary studies evaluating the Catania ™ (CeloNova Biosciences, Newnan, GA, USA) stent in humans demonstrated a good safety profile and high-level efficacy. 28, 29 Efforts to improve polymer stent coatings are ongoing.
Biodegradable polymers
Given the issues of polymer-induced inflammation, thrombo sis, and restenosis, the development of biodegradable polymers has become a focus for research. The most-studied biodegradable polymers are polylactic acid and polylactic-co-glycolic acid, which degrade over time and could, therefore, eliminate the problems associated with lack of polymer biocompatibility and polymer-induced inflammation. To date, several biodegradable polymer stents eluting biolimus A9, sirolimus, or paclitaxel have been clinically evaluated, which have so far proven to be effective and safe in the short term (≤30 days) and midterm (≤1 year). [30] [31] [32] In 2010, the 3-year follow-up data from the LEADERS trial 33 was presented, showing the sustained benefit of BESs with a bio degradable polymer over SESs with a durable polymer. Great expectations exist within the cardio logy community that biodegradable-polymer DESs could become the stents of choice in years to come; the results of the ongoing ISAR-TEST-6 trial, 34 testing the safety and effica cy of the Nobori ® (Terumo Corporation, Tokyo, Japan) bio degradable polymer BES and the Xience V ® permanent polymer ZES will, therefore, be eagerly awaited. New polymer technology presents some challenges, such as establishing the optimal degradation time, biocompatibility, composition, and formulation of the polymer. Several factors influence the velocity of degradation; therefore, the balance between drug-release kineti cs and the rate of polymer degradation, as well as the effects of the degradation products all affect the efficacy of bio degradable polymer stent systems in the coronary vasculature. 35 Furthermore, studies in porcine coronary arteries have shown that even biodegradable polymers can cause inflammatory reactions, which could be attributable to the combination of the parent polymer compound and the bio degradation products. 36 Polymer-free, dual DESs have been tested over the past few years. No apparent benefit was observed by adding estradiol to a polymer-free SES in the ISAR-PEACE trial. 43 However, results from the ISAR-TEST-2 study 44 revealed that a novel, polymer-free sirolimus-eluting and probucoleluting dual DES was noninferior to the Cypher ® SES and the Endeavor ® ZES. The antirestenotic efficacy of both the dual DES and the ZES remained durable during the 2-year follow-up period. 44 The larger ISAR-TEST-5 study, 45 which was powered for clinical events, showed similarly durable results for the dual DES.
Novel prohealing stent coatings
Endothelial progenitor cell-capturing stent An increased rate of endothelialization is thought to lead to reductions in restenosis and stent thrombosis. 46 This hypothesis underlies the development of the endothelial progenitor cell (EPC)-capturing stent. The bioengineered Genous ® (OrbusNeich Medical, Inc.) EPC-capturing stent has a stainless-steel platform that is coated with an abluminal polysaccharide matrix and covalently coupled monoclonal murine antihuman CD34 antibodies. These antibodies bind bone-marrow-derived EPCs from the peripheral blood. These EPCs are hypothesized to differentiate into a functional endo thelial layer after immobilization and populate the surface of the stent. 47 The safety and efficacy of the Genous ® stent have been shown in preliminary human studies, 48, 49 and further evaluation and comparison with other stents is currently ongoing. 50 Despite its benefit in enhancing re-endothelialization, and thereby possibly preventing stent thrombosis, EPC capturing is not expected to potently inhibit neointimal proliferation. On the contrary, CD34 antibodies have even been shown to capture other progenitor cells, for example, smooth muscle cell progenitor cells, which could exagge rate restenosis. 51 Therefore, a major challenge in the develop ment of an EPC-capturing DES is to maintain sustained inhibition of smooth muscle cell proliferation while promoting formation of a functional endothelial layer. This concept was tested in an animal study showing that immobilization of anti-CD34 antibody on SESs enhances endothelialization. 52 The REMEDEE study 38, 53 investigators are currently testing the Combo Stent ® (OrbusNeich Medical, Inc.), which incorporates low-dose abluminal sirolimus together with EPC-capturing technology and a biodegradable polymer. The combination of an EPC-capturing stent with a drug-eluting balloon is also an attractive alternative, as has been shown by the results of the PERFECT STENT study. 54 
Titanium-nitride-oxide-coated stent
The Titan2™ stent (Hexacath, Rueil-Malmaison, France) is a stainless-steel stent coated in titanium-nitride oxide that has been shown to inhibit platelet aggregation, minimize fibrin deposition, reduce inflammation, and promote healing. 55 This stent significantly reduced late lumen loss and TLR compared with a BMS at 6-months follow-up, 56 with preserved benefits up to 5-years. 57 Additionally, the Titan2™ stent demonstrated favorable results compared with the Taxus ® PES in a randomized controlled trial of 425 patients with ST-segment elevation myo cardial infarction, 58 as well as in routine clinical practice. 59 Despite the absence of an antiproliferative drug, use of the Titan2™ stent resulted in less TLR than the Taxus ® stent, although this reduction was not statistically significant. 58 The Titan2™ stent was noninferior to the Xience V ® EES in the primary results of the large randomized controlled BASE-ACS trial 60 conducted in patients with acute coronary syndrome. However, the Titan2™ stent failed to prove noninferiority to the Endeavor ® ZES in terms of angiographic in-stent late lumen loss at 6 months in the TIDE study, 61 although clinical outcomes at 1 year were comparable for both stent types.
Future prohealing stent designs A step further to optimize the prohealing stent design is to create a bioactive stent that also elutes a drug (a bio eluting stent). Animal studies of a newly designed titanium-nitride-oxide stent eluting l-arginine, a precursor of nitric oxide with positive effects on endothelium function, 62 or a sulfated polysaccharide extracted from seaweed have shown up to 50% reduction in late lumen loss compared with the standard titanium-nitride-oxide stent. 63 A future clinical trial (the VINCI first-in-man study) is planned to test the efficacy and safety of this new generation of stents. 63 Another approach to creating a prohealing stent would be to reduce the binding of platelets to an implanted stent, thereby reducing the inflammatory response and allowing surrounding endothelial cells to proper ly re-endothelialize the stent. 64 A stent created from a bioactive ligand, such as an integrin-binding motif, has been successfully used in noncardiac applications in vivo to promote device integration. 65 The ideal ligand should only interact with integrins uniquely present on endothelial cells and not on platelets, inflammatory cells, or smooth muscle cells. 64 Continued in vitro and in vivo studies with such biomaterials could lead to the creation of next-generation prohealing stent surfaces that promote the endothelialization of the stent while simultaneously inhibiting the adhesion and thrombus formation, and not stimulating smooth muscle cell proliferation.
Stent platforms
Metal alloys A platinum-chromium alloy developed in the early 2000s has been combined with everolimus on the Promus Element ® (Boston Scientific) and with paclitaxel on the Taxus Element ® (Boston Scientific) stents, which were granted 'CE' European safety marks in November 2009 and May 2010, respectively. Unlike stainless steel and cobalt-chromium alloys, platinum-chromium has the advantage of increased radial strength enabling the stent to have thinner struts, which have been proven to reduce clinical and angiographic restenosis. 66, 67 In PLATINUM, 68 the Promus Element ® stent was shown to have comparative efficacy and safety when compared with Xience V ® . Similarly, the efficacy and safety of the Taxus Element ® 
Bioabsorbable platforms
The problems encountered with DES have encouraged research into innovative, temporary vascular scaffolds or bioabsorbable stent platforms, which gradually degrade until healing and re-endothelialization have occurred. Eventually, no foreign material is left exposed to the blood, thus mitigating the problem of late stent malapposition and stent thrombosis. These stents have the potential to preserve endothelial function, reactive vasomotion of the artery, and permit late lumen enlargement (expansive remodeling). 71 Initially, a high restenosis rate of 45% was observed in the PROGRESS-AMS trial 72 in which a non-drug-eluting bioabsorbable magnesium stent (Biotronik, Berlin, Germany) was evaluated. Yet more favorable results with stents with a poly-l-lactic acid backbone eluting everolimus (Abbott Vascular, Santa Clara, CA, USA) were reported in the ABSORB trial 71, 73 with sustained clinical benefit at 3-years follow-up. The first generation (revision 1.0) of bioabsorbable vascular scaffolds showed slight signs of shrinkage at 6 months contributing to late luminal loss. 74 However, the second generation (revision 1.1) showed substantial improvements with efficacy comparable to that of current DESs, and enhanced conformability to the angulations and curvatures of the vessel (Figure 2 ).
75,76
Nanomedicine In addition to its promising application in cancer chemotherapy, great interest has been generated in the application of nanotechnology in optimization of local drug delivery. Nanoparticles are liposomes consisting of lipids and polymers that can be loaded with a drug and used to nanotexture stents, in molding processes to make stents, and for drug delivery from stents. 77 Nanoparticle-mediated drug delivery systems are expected to revolu tionize the development of innovative therapeutic devices, allowing local or targeted delivery of the drug with an excellent biocompatibility profile. This strategy controls the concentration and duration of drug release, thereby potentially reducing systemic toxicity. 78 Of the drugs investigated for restenosis prevention and treatment, only paclitaxel and sirolimus have been successfully administered through nanoparticle-based delivery systems and only in preclinical studies. 79, 80 Paclitaxel eluted from a cobalt-chromium stent coated with porous carbon-carbon nanoparticles showed promising results with respect to endothelialization and neointimal hyperplasia. 79 Sirolimus incorporated into nanoparticle delivery systems (poly-d,l-lactide) showed improved release kinetics. 80 Furthermore, these sirolimusloaded nanovehicles selectively inhibited cell viability and proliferation of cultured human coronary artery smooth muscle cells, while human coronary artery endothelial cells were inhibited to a lesser extent. Endothelial cells were, therefore, left viable to a degree that allowed re-endothelialization of the stented vessel, yet smooth muscle cell proliferation was still prevented. 80 In another approach, Chorny et al. investigated the novel concept of 'magnetic targeting stents' by combining uniform field-induced magnetization and a biocompatible magnetic nanoparticle formulation in a rat model of carotid stenting. 81 Magnetic targeting allows a drug to be delivered on demand to an in vivo site with various dosing regimens. These investigators demonstrated that the magnetic nanoparticles loaded with paclitaxel adequately inhibited neointima formation after uniform-field-controlled targeting when compared with nonmagnetically treated animals. 81 Nanomedicine is, therefore, an innovative and promising perspective in stent design, but has yet to be demonstrated as safe and effective in clinical practice.
Gene-based therapy
Gene-based therapy has emerged over the past few years as a promising tool for the prevention of ISR. Numerous transgenes have been shown to be effective in reducing ISR in animal models (Table 2 ) and various modes of local gene delivery have been developed. An effective method of gene delivery is by means of 'gene-eluting stents' , which elute plasmid DNA or adenoviral vectors. 82, 83 Pyrroleimidazole polyamide is a powerful gene-regulating compound ('gene silencer') that inhibits the interaction between proteins, such as transcription factors, and DNA. 84 An in vivo animal study conducted by Yao et al. showed that synthetic pyrrole-imidazole polyamide can suppress neointimal hyperplasia by down regulation of transforming growth factor β1 and connective tissue growth factor, 85 as well as monocyte chemotactic protein 1, matrix metalloproteinase 9, and intercellular adhesion molecule 1, 86 making it a promising next-generation agent.
Nuclear 'orphan' receptors comprise a group of ligandactivated receptors for which specific ligands have not yet been identified, but which are known to directly bind and interact with the promoter of target genes. 87 Nuclear receptor related proteins 1 and 77 have been identified as having a role in ISR development; overexpression of these proteins inhibits intimal proliferation and ISR in animal models. 88, 89 A small-molecule drug that enhances the activity of these receptors, namely 6-mercaptopurine, represents an attractive novel target for local intervention in restenosis. 89 Finally, reducing the proliferative capacity of vascular smooth muscle cells could be of benefit in reducing neointimal hyperplasia following PCI. The biology of microRNAs and their ability to modify smooth muscle biology has been reviewed by O'Sullivan and colleagues. 90 Two microRNAs, mir-143 and mir-145, were shown to have a key role in the regulation of vascular smooth muscle cells in vivo and might, therefore, have therapeutic potential.
Systemic treatment
Since local drug delivery does not eradicate ISR completely, systemic treatment has also been explored, despite the obvious risk of adverse effects. We will briefly discuss the evidence for the antirestenotic effects of several antiproliferative and anti-inflammatory drugs.
The major role of the inflammatory system in restenosis formed the rationale for using prednisone for the prevention of this condition. The IMPRESS trial 91 showed favorable results with oral prednisone in patients undergoing coronary BMS implantation both in angiographic and clinical outcomes. In addition, a subanalysis from the ongoing CEREA-DES trial, 92 reported by Pesarini et al. in 2010, 93 showed that high doses of oral prednisone reduced late lumen loss, probably via a reduction in the release of tumor necrosis factor.
Preclinical studies have demonstrated that systemically administered sirolimus (rapamycin) reduces neointimal proliferation after vascular injury. 94 Several clinical trials confirmed the benefit of oral sirolimus in reducing ISR after BMS implantation, 95, 96 making it a possible effective and cost-saving alternative to DES implantation. However, the long-term results of the OSIRIS trial, 97 reported by Kufner and co-workers in 2009, showed an attenuated benefit of oral sirolimus after 4 years and, moreover, raised concerns regarding a related increase in newly diagnosed malignancies.
Cilostazol, a phosphodiesterase III inhibitor, has antiproliferative effects 98 and has been shown to reduce intimal hyperplasia and restenosis after both BMS and DES implantation. 99, 100 In a meta-analysis published in 2011, Kamal et al. concluded that addition of cilostazol to standard dual antiplatelet therapy reduces angiographic restenosis without significantly affecting rates of major adverse cardiac events or bleeding. 101 However, cilostazo l was associated with an increase in the incidence of minor adverse effects, such as headaches, gastrointestinal complaints, and palpitations. 102 Pioglitazone, a thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, is used for the treatment of diabetes. An additional antiatherogenic effect of the drug in vascular cells limiting lesion develop ment in animal models of atheros clerosis has been described. 103 Several clinical studies have demonstrated a reduced incidence of ISR after stent deployment with thiazolidinedione (pioglitazone or rosiglitazone) administration. 104, 105 Although rates of ISR have been shown to be reduced with the systemic use of various drugs, the concen tration of drug accumulated at the site of interest is limited by toxicity. Systemic treatment will, therefore, probably never be superior to local drug delivery with DESs. This strategy could, however, be useful as an adjunct to BMS implantation.
Restenosis: presentation and outcomes
If measures to prevent the development of restenosis fail, the clinical presentation of this condition is not always benign and can have a spectrum of acuity. 106 Multiple mechanisms underlie myocardial infarction associated with ISR. An occlusive restenosis can be difficult to differentiate from a thrombotic event and a highly stenotic ISR lesion can promote local nonocclusive thrombosis and lead to a clinical presentation of non-ST-segment elevation myocardial infarction or troponin-positive unstable coronary syndrome. 107 Whether a difference exists between the use of DESs and BMSs in this entity of 'thrombosis on top of restenosis' remains to be elucidated. A pathology study by Nakazawa et al. confirmed the occurrence of neoatherosclerosis in the neointimal growth after implantation of both BMSs and DESs, but unstable features of neoatherosclerosis were encountered more frequently and earlier with DESs. 108 Whether this finding translates into a difference in outcomes between stent types is still questionable. 109 One factor that does influence outcomes associated with ISR is the angiographic pattern of restenosis (Figure 3) , which can be broadly classified into focal (<10 mm) and nonfocal (>10 mm) lesions. Mehran et al. showed that the pattern of ISR independently predicts the long-term need for revascularization, with an increase in the rate of TLR with increasing ISR class. 110 The morphologic patterns of DES restenosis are different from those of BMS, favoring a more focal and easily treated pattern with expected improved clinical outcomes. 111 In DES-treated patients, the rates of TLR were significantly higher in diffuse ISR compared with focal ISR. 112 
Treatment of restenosis
The optimal treatment for ISR remains debatable. The options include vascular brachytherapy; conventional balloon, cutting balloon, or drug-eluting balloon angioplasty; BMS or DES implantation; and CABG surgery. This diversity of available treatments and the variability in the underlying etiology of restenosis make selection of the most appropriate modality difficult. In other words, the treatment of ISR should be tailored and indivi dualized according to the clinical situation and in view of the underlying etiological factors. Several of the treatment options for restenosis are discussed in detail below.
Vascular brachytherapy
Intracoronary brachytherapy was once recommended as an effective treatment for ISR on the basis of data from several randomized, controlled trials published in the early 2000s.
113,114 Antiproliferative δ (iridium-192) or β (phosphorus-32) irradiation is delivered locally to the target lesions via dedicated catheters. Currently, however, brachytherapy with either β or δ radiation is of very limited use. The difficulty in performing this procedure, particularly handling the radioactive substances, and the increasingly widespread use of DESs has gradually displaced brachytherapy from the armamentarium of the interventionist. Nevertheless, the 5-year follow-up data from the SISR study, presented at the 2011 ACC i2 summit, suggest that brachytherapy could be an equivalent treatment option to SES implantation for the treatment of ISR. 115 Cutting-balloon angioplasty The cutting balloon consists of a balloon catheter with three to four blades or 'atherotomes' designed to create discrete longitudinal incisions in the atherosclerotic lesion during balloon inflation. Such controlled dilatation theoreti cally reduces the force needed to dilate an obstructive lesion compared with standard balloon angioplasty and avoid slipping-induced vessel trauma during PCI, potentially decreasing the risk of ISR development. 116 Although this expected benefit was not demonstrated when the device first came into use in the early 1990s, 117 the later REDUCE III study did show that an IVUS-guided cutting balloon procedure followed by BMS implantation yielded restenosis rates similar to Type ID: multifocal REVIEWS those achieved with DESs, thereby, providing an effective alternative. 118 However, use of the cutting balloon remains uncommon for the treatment of ISR, especially when used without stent placement. In 2010, Park et al. raised concerns that cutting-balloon angioplasty might be associ ated with a higher risk of myocardial infarction than conventional balloon angioplasty; 119 this technique is, therefore, unlikely to become an important ISR treatment modality.
Drug-eluting balloon angioplasty
Non-stent-based local delivery of an antiproliferative drug, particularly using drug-eluting balloons, theoretically represents a very attractive treatment for ISR that avoids the limitations associated with DES platforms. Drug-eluting balloons improve drug delivery by allowing homogenous drug transfer to the entire vessel wall rather than only to the areas covered by stent struts, as with DESs. All currently available drug-eluting balloons use paclitaxel in various coating formulations with a typical dose of 3 µg/mm 2 of balloon surface. Drug-eluting balloon angioplasty has been shown to be more effective than conventional balloon angioplasty, 120 and as effectiveas PES implantation 121 for the treatment of ISR. However, drug-eluting balloons of course cannot prevent the almost immediate elastic recoil phenomenon.
Currently, research in this area is focused on comparisons of the various available drug-eluting balloons. Aachen, Germany; 2.0 µg/mm 2 paclitaxel) all resulted in delayed healing when compared with conventional balloon angioplasty. 122 However, the investigators also demonstrated signifi cant heterogeneity in neointimal suppression between the balloons, with superiority of Pantera ® Lux. 115 This difference was attributed to the 'excipient' used as an effective carrier for paclitaxel in the Pantera ® Lux and SeQuent ® Please balloons. The 6-month results of the PEPPER trial, 123 which were presented at the ACC i2 summit in April 2011, showed excellent results for the Pantera ® Lux balloon for the treatment of ISR both in BMSs and DESs. However, a subgroup analysis revealed a significantly lower instent late lumen loss in BMS-related ISR compared with DES-related ISR, suggesting that the drug effect of the balloon may be decreased in patients with DES-related ISR and may differ between DES drug types. A higher number of patients with diabetes in the DES-related ISR group may have confounded the results. 124 In the 2010 guidelines for myocardial revascularization published by the European Society of Cardiology, drugeluting balloons were considered a class IIa indication for the treatment of ISR. 125 Nevertheless, further large studies need to be implemented before these devices can be fully integrated into clinical practice. Patients are currently being recruited for an ongoing trial 126 to investigate the efficacy of a drug-eluting balloons for the treatment of ISR in patients with DESs.
Drug-eluting stents
DESs are known to have fairly low rates of ISR. 4, 5 The proportion of restenotic lesions treated with DES in the studies providing this data is, however, low. Since resteno tic lesions have a tendency towards recurrent restenosis, as discussed in Part 1 of this Review, 6 the outcomes associated with stent (DES) implantation in these lesions is likely to be different to those for DES placement in de novo lesions. In addition, ISR after BMS implantation differs from ISR associated with DES use and, therefore, a distinction between these two types of restenosis should also be made in terms of treatment.
Favorable outcomes of DES treatment for BMS-related ISR have been reported in several studies, even after longterm follow up. [118] [119] [120] [121] Treatment with DES placement was found to be more effective and safer than conventional balloon angioplasty, 127 vascular brachytherapy, 128, 129 or BMS implantation within the original stent. 130 DESs should, therefore, be the treatment of choice for the treatment of BMS-related ISR. By contrast, the same cannot be said for DES-related ISR, which continues to be a therapeutic challenge. To date, the treatment of this condi tion has been investigated in only one randomized controlled trial, which showed comparable efficacy for SES re implantation or a switch to PES implantation in patients with SES-related ISR. 131 Other small non randomized trials have produced inconsistent results, limiting the possibility of drawing any definitive conclusions about the optimal treatment of DES-related ISR. 107 An individual's resistance to a particular eluted drug can be a factor in restenosis development. 132, 133 This hypothesis provides the rationale for switching to a different DES for the treatment of DES-related ISR. However, to date, no clinical study has demonstrated clear clinical benefit of implanting an alternative different DES. 131, 134 Whether resistance to sirolimus also implies resistance to other limus derivatives remains questionable, as no reports have been published on the use of zotarolimus, everolimus, or biolimus A9-eluting stents for the treatment of SES-related ISR. Another uncertainty is whether the angiographic pattern of DES-related ISR provides a clue to the involvement of drug resistance. Drug resistance is expected to cause a diffuse pattern of ISR, so perhaps a future study focused on patients with diffuse patterns of ISR would clarify the potential benefits of changing the agent eluted by the stent. In the ongoing prospective, randomized Italian GISE-CROSS trial, 135 treatment with a stent that elutes the same drug as the original restenosed stent (no CROSS group) is being compared with a crossover to an alternative DES in patients with ISR after either PES or SES implantation. The results of this study are eagerly awaited. Patients treated with DES for ISR are at high risk for recurrent ischemic events and should be maintained on dual antiplatelet therapy unless a complication emerges. 107 Therefore, individuals who have a contra indication for, or show noncompliance with, dual antiplatelet therapy should be considered for CABG surgery.
CABG surgery CABG surgery is usually considered as the 'last resort' treatment for ISR in the clinic. However, this strategy is an appropriate first-line therapy for certain complex cases, such as multivessel ISR, diffuse ISR, multiple subsequent DES restenosis treated by repeat DES implantation, a strong genetic predisposition to ISR that precludes further interventional options, or in cases where dual anti platelet therapy is not appropriate, as discussed above. To our knowledge, no studies of CABG surgery for the treatment of in-stent restenosis have been conducted.
Conclusions
Restenosis is a complex disease with a diversity of underlying mechanisms that are still not fully understood. Many innovative technologies, including DESs (with or without specific polymers) and fully biodegradable stents, have been and continue to be developed in the diligent search for an ideal antirestenosis therapy that is both effective and safe in the long term. Developments in the field of gene therapy might also impact future restenosis therapies. Advances in stent design and nanoparticle delivery systems ('nanovehicles') in the past 5 years have already fueled revo lutionary changes in the concept of ISR prevention and treatment. In addition, several clinical algorithms for ISR treatment have been proposed on the basis of angiographic pattern of restenosis. 107, 135, 136 Treatment of ISR should be tailored to the individual, taking into consideration the available evidence and the best strategy for the patient, as well as the best method of treating the lesion. We believe that investing in the prevention of ISR is worth much more than investing in its treatment.
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